Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00242502 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT00242502: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00242502 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 62 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00242502, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
The primary objective will be to assess progression-free survival (PFS) measured at 16 weeks following initiation of therapy with the combination of Avastin and erlotinib in patients with unresectable hepatocellular carcinoma (HCC). Progression-free survival is defined as the time from initiation of therapy until documented disease progression or death. Secondary objectives include: response rate, median and overall survival, toxicity and tolerability, and to ascertain whether there is any correlation of response with prior treatment status and underlying HCC risk factor(s).
Interventions
- DRUG Erlotinib
- DRUG Bevacizumab (Avastin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2005-10 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00242502
The ClinicalTrials.gov registry entry for NCT00242502 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Erlotinib is the first listed.
NCT00242502 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00242502 about?
NCT00242502 is a clinical study titled "Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery". The primary objective will be to assess progression-free survival (PFS) measured at 16 weeks following initiation of therapy with the combination of Avastin and erlotinib in patients with unresectable hepatocellular carcinoma (HCC). Progression-free survival is defined as the time from initiation of...
What is the current status of trial NCT00242502?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2005-10. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00242502?
The interventions under investigation include: Erlotinib (DRUG), Bevacizumab (Avastin) (DRUG).
Who is sponsoring clinical trial NCT00242502?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.